Literature DB >> 16620197

Managing the burden of chronic kidney disease.

Micah L Thorp1, Loris Eastman, David H Smith, Eric S Johnson.   

Abstract

Patients with chronic kidney disease (CKD) have high rates of healthcare utilization, morbidity, and mortality. Increasing rates of obesity, diabetes, and hypertension suggest that the expected numbers of patients with CKD will rise. Managing the economic and clinical burden of CKD will be a significant challenge for the healthcare system. The burden of CKD can be considered in terms of both CKD-specific and CKD-related morbidity and mortality. CKD-specific complications include anemia and bone disease. CKD-related complications include obesity, diabetes and hypertension. CKD-specific complications tend to occur later in the course of disease and may be best treated by a nephrologist, while CKD-related complications may be most easily treated by primary care physicians. Coordinating patient care is essential to managing the burden of this growing disease.

Entities:  

Mesh:

Year:  2006        PMID: 16620197     DOI: 10.1089/dis.2006.9.115

Source DB:  PubMed          Journal:  Dis Manag        ISSN: 1093-507X


  9 in total

1.  Effects of amino acids and albumin on erythropoietin carbamoylation.

Authors:  Kyubok Jin
Journal:  Clin Exp Nephrol       Date:  2012-12-11       Impact factor: 2.801

2.  A nurse-coordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: a randomized controlled trial.

Authors:  Brendan J Barrett; Amit X Garg; Ron Goeree; Adeera Levin; Anita Molzahn; Claudio Rigatto; Joel Singer; George Soltys; Steven Soroka; Dieter Ayers; Patrick S Parfrey
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-26       Impact factor: 8.237

3.  Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective.

Authors:  Amisha M Parikh; Frederick A Spencer; Darleen Lessard; Catherine Emery; Ana Baylin; Crystal Linkletter; Robert J Goldberg
Journal:  Am J Kidney Dis       Date:  2011-08-27       Impact factor: 8.860

4.  Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005-2008: is treatment with bisphosphonates an option?

Authors:  R Lubwama; A Nguyen; A Modi; D Chirovsky; C Diana; P D Miller
Journal:  Osteoporos Int       Date:  2014-02-28       Impact factor: 4.507

5.  High burden and unmet patient needs in chronic kidney disease.

Authors:  Leeann Braun; Vipan Sood; Susan Hogue; Bonnie Lieberman; Catherine Copley-Merriman
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-12-13

6.  Urinary adiponectin as a new diagnostic index for chronic kidney disease due to diabetic nephropathy.

Authors:  Shinnosuke Yamakado; Hiroki Cho; Mikio Inada; Mika Morikawa; Yong-Huang Jiang; Kenji Saito; Kazunari Nakaishi; Satoshi Watabe; Hitomi Takagi; Mugiho Kaneda; Akira Nakatsuma; Masaki Ninomiya; Hitomi Imachi; Takeshi Arai; Takuo Yoshimoto; Koji Murao; Jyun-Hao Chang; Shih-Min Chen; Yi-Chen Shih; Min-Jing Zeng; Liang-Yin Ke; Chu-Huang Chen; Teruki Yoshimura; Toshiaki Miura; Etsuro Ito
Journal:  BMJ Open Diabetes Res Care       Date:  2019-05-30

7.  Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation.

Authors:  Vanesa Esteban; Silvia Heringer-Walther; Anja Sterner-Kock; Ron de Bruin; Sandra van den Engel; Yong Wang; Sergio Mezzano; Jesus Egido; Heinz-Peter Schultheiss; Marta Ruiz-Ortega; Thomas Walther
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

8.  The prevalence of chronic kidney disease in a primary care setting: a Swiss cross-sectional study.

Authors:  Yuki Tomonaga; Lorenz Risch; Thomas D Szucs; Patrice M Ambühl; Patrice M Ambuehl
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

9.  Higher serum direct bilirubin levels were associated with a lower risk of incident chronic kidney disease in middle aged Korean men.

Authors:  Seungho Ryu; Yoosoo Chang; Yiyi Zhang; Hee-Yeon Woo; Min-Jung Kwon; Hyosoon Park; Kyu-Beck Lee; Hee Jung Son; Juhee Cho; Eliseo Guallar
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.